BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18535393)

  • 21. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: a prospective study.
    Lumachi F; Camozzi V; Ermani M; DE Lotto F; Luisetto G
    Ann N Y Acad Sci; 2007 Nov; 1117():357-61. PubMed ID: 17646261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
    Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
    Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse association of serum long-acting natriuretic peptide and bone mineral density in renal transplant recipients.
    Hsu BG; Ho GJ; Lee CJ; Yang YC; Chen YC; Shih MH; Lee MC
    Clin Transplant; 2012; 26(2):E105-10. PubMed ID: 22211802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for changes in bone mineral density and the effect of antiosteoporosis management after renal transplantation.
    Ahn HJ; Kim HJ; Kim YS; Kim MS; Huh KH; Kim JH; Lee JH; Jeon KO; Kim SI
    Transplant Proc; 2006 Sep; 38(7):2074-6. PubMed ID: 16980003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Parathyroid function in hyperthyroidism: implications for bone metabolism and effect of the treatment].
    Furlanetto RP; Castro ML; de Mesquita CH; Kasamatsu TS; Vieira JG
    Rev Paul Med; 1991; 109(2):55-60. PubMed ID: 1909454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parathyroid hormone and bone metabolism in kidney-transplanted patients.
    D'Angelo A; Calò L; Giannini S; Carraro G; Bonfante L; Favaro S; Zaninotto M; Perin N; Di Landro D; Rigotti P; Antonello A
    Clin Nephrol; 2000 Apr; 53(4):suppl 19-22. PubMed ID: 10809430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for osteoporosis in young renal transplant recipients.
    Sezer S; Ozdemir FN; Ibis A; Sayin B; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3116-8. PubMed ID: 16213324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases.
    Bai XL; Liang TB; Wu LH; Li DL; Geng L; Wang WL; Shen Y; Zhang M; Zheng SS
    Transplant Proc; 2007 Dec; 39(10):3182-5. PubMed ID: 18089348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of early loss of bone mineral density after liver transplantation by prostaglandin E1.
    Hommann M; Kämmerer D; Lehmann G; Kornberg A; Küpper B; Daffner W; Wolf G; Settmacher U
    Transplant Proc; 2007 Mar; 39(2):540-3. PubMed ID: 17362777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin.
    Zadrozna-Sliwka B; Bolanowski M; Jawiarczyk A; Kaluzny M; Syrycka J
    Neuro Endocrinol Lett; 2008 Feb; 29(1):178-84. PubMed ID: 18283239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone mineral density in kidney transplant recipients and patients on hemodialysis: a comparison with healthy individuals.
    Nouri-Majalan N; Sanadgol H; Rahimian M; Soleimani H
    Iran J Kidney Dis; 2008 Jul; 2(3):154-9. PubMed ID: 19377230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation.
    Yao S; Smiley SL; West K; Lamonica D; Battiwalla M; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1130-7. PubMed ID: 20188201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry.
    Nayak B; Guleria S; Varma M; Tandon N; Aggarwal S; Bhowmick D; Agarwal SK; Mahajan S; Gupta S; Tiwari SC
    Transplant Proc; 2007 Apr; 39(3):750-2. PubMed ID: 17445589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary hyperparathyroidism is associated with vitamin D receptor polymorphism and bone density after renal transplantation.
    Rubello D; Giannini S; D'Angelo A; Nobile M; Carraio G; Rigotti P; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Nibale O; Carpi A
    Biomed Pharmacother; 2005 Aug; 59(7):402-7. PubMed ID: 16084056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone mineral density of the spine and femur in a group of healthy Moroccan men.
    El Maghraoui A; Ghazi M; Gassim S; Mounach A; Ghozlani I; Nouijai A; Achemlal L; Bezza A; Dehhaoui M
    Bone; 2009 May; 44(5):965-9. PubMed ID: 19168162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
    Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
    Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.
    Kanaan N; Claes K; Devogelaer JP; Vanderschueren D; Depresseux G; Goffin E; Evenepoel P
    Clin J Am Soc Nephrol; 2010 Oct; 5(10):1887-92. PubMed ID: 20634326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of regional bone mineral density in the first 12 months following renal transplantation.
    Almond MK; Kwan JT; Evans K; Cunningham J
    Nephron; 1994; 66(1):52-7. PubMed ID: 8107953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.